US Supreme Court supports MedImmune's position in patent dispute with Genentech |
|
|
|
Published
:
Wed, 10 Jan 2007 08:57
|
ZURICH - The US Supreme Court in Washington has ruled that US biotech company MedImmune Inc does not infringe a Genentech Inc production-patent known as Cabilly-II, thus enabling MedImmune to go ahead with its own related lawsuit against Genentech.MedImmune had previously disputed the patent, but had continued to pay royalties to Genentech, which is majority-owned by Swiss pharma group Roche Holding AG.The Cabilly patent is used by MedImmune to make Synagis, a drug that treats childhood respiratory problems.afx.zurich@afxnews.comat/icCOPYRIGHTCopyright AFX News Limited 2006. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Court rules in favor of MedImmune 